Treatment outcomes in the DRy Eye Amniotic Membrane (DREAM) study

Marguerite B McDonald,1 Hosam Sheha,2–5 Sean Tighe,2,3 Susan B Janik,6 Frank W Bowden,7 Amit R Chokshi,8 Michael A Singer,9 Seema Nanda,10 Mujtaba A Qazi,11 Damon Dierker,12 Adam T Shupe,13 Brittany J McMurren14 1Ophthalmic Consultants of Long Island, Lynbrook, NY, USA; 2Ocular Surface Ce...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	McDonald MB, Sheha H, Tighe S, Janik SB, Bowden FW, Chokshi AR, Singer MA, Nanda S, Qazi MA, Dierker D, Shupe AT, McMurren BJ
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	Amniotic membrane Dry eye Ocular Surface. Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/2e6e74608377402b9eda4e8b04a40fe3
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2e6e74608377402b9eda4e8b04a40fe3
record_format	dspace
spelling	oai:doaj.org-article:2e6e74608377402b9eda4e8b04a40fe32021-12-02T07:44:14ZTreatment outcomes in the DRy Eye Amniotic Membrane (DREAM) study1177-5483https://doaj.org/article/2e6e74608377402b9eda4e8b04a40fe32018-04-01T00:00:00Zhttps://www.dovepress.com/treatment-outcomes-in-the-dry-eye-amniotic-membrane-dream-study-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Marguerite B McDonald,1 Hosam Sheha,2–5 Sean Tighe,2,3 Susan B Janik,6 Frank W Bowden,7 Amit R Chokshi,8 Michael A Singer,9 Seema Nanda,10 Mujtaba A Qazi,11 Damon Dierker,12 Adam T Shupe,13 Brittany J McMurren14 1Ophthalmic Consultants of Long Island, Lynbrook, NY, USA; 2Ocular Surface Center and TissueTech, Inc., Miami, FL, USA; 3Florida International University Herbert Wertheim College of Medicine, Miami, FL, USA; 4Hofstra University School of Medicine, Hempstead, NY, USA; 5Research Institute of Ophthalmology, Cairo, Egypt; 6Solinsky Eye Care, Kensington, CT, USA; 7Bowden Eye & Associates, Jacksonville, FL, USA; 8Florida Eye Specialists, Jacksonville, FL, USA; 9Medical Center Ophthalmology Associates, San Antonio, TX, USA; 10TX Eye Institute, Houston, TX, USA; 11Pepose Vision Institute, Chesterfield, MO, USA; 12Eye Surgeons of Indiana, Indianapolis, IN, USA; 13Royo Eye Care, Marysville, CA, USA; 14Gordon and Weiss Vision Institute, San Diego, CA, USA Purpose: To evaluate the efficacy of cryopreserved amniotic membrane (CAM) in reducing signs and symptoms of dry eye disease (DED) in a large patient population. Methods: A retrospective chart review at 10 clinical sites was done of patients with refractory DED who received CAM and completed at least 3 months of follow-up. Data collected were demographics; medical history including previous and current ocular treatment, diagnosis, clinical presentations, comorbidity, duration and frequency of treatment with CAM; and concomitant medications. The primary outcome was the change in dry eye workshop (DEWS) score after treatment. Results: A total of 97 eyes of 84 patients exhibited severe dry eye despite maximal medical treatments including topical artificial tears, cyclosporine-A, serum, antibiotics, and steroids. Patients manifested with superficial punctate keratitis (86%), filamentary keratitis (13%), exposure keratitis (19%), neurotrophic keratitis (2%), and corneal epithelial defect (7%). After CAM treatment for 5.4±2.8 days, 74 (88%) patients demonstrated an improved ocular surface along with a notable reduction of the severity as the overall DEWS score was significantly reduced from 3.25±0.5 at baseline to 1.44±0.6 at 1 week, 1.45±0.6 at 1 month, and 1.47±0.6 at 3 months (p<0.001). Ten eyes (10%) required repeated treatment to complete healing. Apart from discomfort during CAM placement, there were no adverse events. Conclusion: Placement of CAM is promising to enhance the recovery of ocular surface health and reduce signs and symptoms in patients with moderate-to-severe DED. Keywords: amniotic membrane, dry eye, ocular surface, severity, DEWSMcDonald MBSheha HTighe SJanik SBBowden FWChokshi ARSinger MANanda SQazi MADierker DShupe ATMcMurren BJDove Medical PressarticleAmniotic membraneDry eyeOcular Surface.OphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 12, Pp 677-681 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Amniotic membrane Dry eye Ocular Surface. Ophthalmology RE1-994
spellingShingle	Amniotic membrane Dry eye Ocular Surface. Ophthalmology RE1-994 McDonald MB Sheha H Tighe S Janik SB Bowden FW Chokshi AR Singer MA Nanda S Qazi MA Dierker D Shupe AT McMurren BJ Treatment outcomes in the DRy Eye Amniotic Membrane (DREAM) study
description	Marguerite B McDonald,1 Hosam Sheha,2–5 Sean Tighe,2,3 Susan B Janik,6 Frank W Bowden,7 Amit R Chokshi,8 Michael A Singer,9 Seema Nanda,10 Mujtaba A Qazi,11 Damon Dierker,12 Adam T Shupe,13 Brittany J McMurren14 1Ophthalmic Consultants of Long Island, Lynbrook, NY, USA; 2Ocular Surface Center and TissueTech, Inc., Miami, FL, USA; 3Florida International University Herbert Wertheim College of Medicine, Miami, FL, USA; 4Hofstra University School of Medicine, Hempstead, NY, USA; 5Research Institute of Ophthalmology, Cairo, Egypt; 6Solinsky Eye Care, Kensington, CT, USA; 7Bowden Eye & Associates, Jacksonville, FL, USA; 8Florida Eye Specialists, Jacksonville, FL, USA; 9Medical Center Ophthalmology Associates, San Antonio, TX, USA; 10TX Eye Institute, Houston, TX, USA; 11Pepose Vision Institute, Chesterfield, MO, USA; 12Eye Surgeons of Indiana, Indianapolis, IN, USA; 13Royo Eye Care, Marysville, CA, USA; 14Gordon and Weiss Vision Institute, San Diego, CA, USA Purpose: To evaluate the efficacy of cryopreserved amniotic membrane (CAM) in reducing signs and symptoms of dry eye disease (DED) in a large patient population. Methods: A retrospective chart review at 10 clinical sites was done of patients with refractory DED who received CAM and completed at least 3 months of follow-up. Data collected were demographics; medical history including previous and current ocular treatment, diagnosis, clinical presentations, comorbidity, duration and frequency of treatment with CAM; and concomitant medications. The primary outcome was the change in dry eye workshop (DEWS) score after treatment. Results: A total of 97 eyes of 84 patients exhibited severe dry eye despite maximal medical treatments including topical artificial tears, cyclosporine-A, serum, antibiotics, and steroids. Patients manifested with superficial punctate keratitis (86%), filamentary keratitis (13%), exposure keratitis (19%), neurotrophic keratitis (2%), and corneal epithelial defect (7%). After CAM treatment for 5.4±2.8 days, 74 (88%) patients demonstrated an improved ocular surface along with a notable reduction of the severity as the overall DEWS score was significantly reduced from 3.25±0.5 at baseline to 1.44±0.6 at 1 week, 1.45±0.6 at 1 month, and 1.47±0.6 at 3 months (p<0.001). Ten eyes (10%) required repeated treatment to complete healing. Apart from discomfort during CAM placement, there were no adverse events. Conclusion: Placement of CAM is promising to enhance the recovery of ocular surface health and reduce signs and symptoms in patients with moderate-to-severe DED. Keywords: amniotic membrane, dry eye, ocular surface, severity, DEWS
format	article
author	McDonald MB Sheha H Tighe S Janik SB Bowden FW Chokshi AR Singer MA Nanda S Qazi MA Dierker D Shupe AT McMurren BJ
author_facet	McDonald MB Sheha H Tighe S Janik SB Bowden FW Chokshi AR Singer MA Nanda S Qazi MA Dierker D Shupe AT McMurren BJ
author_sort	McDonald MB
title	Treatment outcomes in the DRy Eye Amniotic Membrane (DREAM) study
title_short	Treatment outcomes in the DRy Eye Amniotic Membrane (DREAM) study
title_full	Treatment outcomes in the DRy Eye Amniotic Membrane (DREAM) study
title_fullStr	Treatment outcomes in the DRy Eye Amniotic Membrane (DREAM) study
title_full_unstemmed	Treatment outcomes in the DRy Eye Amniotic Membrane (DREAM) study
title_sort	treatment outcomes in the dry eye amniotic membrane (dream) study
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/2e6e74608377402b9eda4e8b04a40fe3
work_keys_str_mv	AT mcdonaldmb treatmentoutcomesinthedryeyeamnioticmembranedreamstudy AT shehah treatmentoutcomesinthedryeyeamnioticmembranedreamstudy AT tighes treatmentoutcomesinthedryeyeamnioticmembranedreamstudy AT janiksb treatmentoutcomesinthedryeyeamnioticmembranedreamstudy AT bowdenfw treatmentoutcomesinthedryeyeamnioticmembranedreamstudy AT chokshiar treatmentoutcomesinthedryeyeamnioticmembranedreamstudy AT singerma treatmentoutcomesinthedryeyeamnioticmembranedreamstudy AT nandas treatmentoutcomesinthedryeyeamnioticmembranedreamstudy AT qazima treatmentoutcomesinthedryeyeamnioticmembranedreamstudy AT dierkerd treatmentoutcomesinthedryeyeamnioticmembranedreamstudy AT shupeat treatmentoutcomesinthedryeyeamnioticmembranedreamstudy AT mcmurrenbj treatmentoutcomesinthedryeyeamnioticmembranedreamstudy
_version_	1718399210145972224

Treatment outcomes in the DRy Eye Amniotic Membrane (DREAM) study

Ejemplares similares